Research ArticleArticle
Automated Measurement of Microvascular Function Reveals Dysfunction in Systemic Sclerosis: A Cross-sectional Study
Daniel R. Machin, Phillip E. Gates, Hans Vink, Tracy M. Frech and Anthony J. Donato
The Journal of Rheumatology September 2017, jrheum.170120; DOI: https://doi.org/10.3899/jrheum.170120
Daniel R. Machin
From the University of Utah, Department of Internal Medicine, and the Department of Exercise and Sport Science, and the Department of Biochemistry; VA Salt Lake City, Geriatric Research, Education, and Clinical Center (GRECC), Salt Lake City, Utah, USA; Maastricht University, Department of Physiology, Maastricht, the Netherlands; MicroVascular Health Solutions LLC, Alpine, Utah, USA. Supported by the US National Institutes of Health (R01 AG040297 to AJD, K23 AR067889 to TMF, and K02 AG045339 to AJD); and the US Department of Veterans Affairs (I01 CX001183 to TMF). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. HV is chief scientific officer at MicroVascular Health Solutions LLC and reports personal fees from GlycoCheck BV and MicroVascular Health Solutions LLC outside the submitted work. In addition, HV has a patent (WO2009068685): Diagnostic and Therapeutic Tools for Diseases Altering Vascular Function. D.R. Machin, PhD, University of Utah, Department of Internal Medicine, and VA Salt Lake City, GRECC; P.E. Gates, PhD, University of Utah, Department of Internal Medicine; H. Vink, PhD, Maastricht University, Department of Physiology, and MicroVascular Health Solutions LLC; T.M. Frech, MD, University of Utah, Department of Internal Medicine; A.J. Donato, PhD, University of Utah, Department of Internal Medicine, Department of Exercise and Sport Science, Department of Biochemistry, and VA Salt Lake City, GRECC. Address correspondence to A.J. Donato, VA Medical Center, SLC, 500 Foothill Drive, GRECC, Bldg 2, Rm 2D15A, Salt Lake City, Utah 84148, USA. E-mail: tony.donato@utah.edu. Accepted for publication June 21, 2017.
Phillip E. Gates
From the University of Utah, Department of Internal Medicine, and the Department of Exercise and Sport Science, and the Department of Biochemistry; VA Salt Lake City, Geriatric Research, Education, and Clinical Center (GRECC), Salt Lake City, Utah, USA; Maastricht University, Department of Physiology, Maastricht, the Netherlands; MicroVascular Health Solutions LLC, Alpine, Utah, USA. Supported by the US National Institutes of Health (R01 AG040297 to AJD, K23 AR067889 to TMF, and K02 AG045339 to AJD); and the US Department of Veterans Affairs (I01 CX001183 to TMF). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. HV is chief scientific officer at MicroVascular Health Solutions LLC and reports personal fees from GlycoCheck BV and MicroVascular Health Solutions LLC outside the submitted work. In addition, HV has a patent (WO2009068685): Diagnostic and Therapeutic Tools for Diseases Altering Vascular Function. D.R. Machin, PhD, University of Utah, Department of Internal Medicine, and VA Salt Lake City, GRECC; P.E. Gates, PhD, University of Utah, Department of Internal Medicine; H. Vink, PhD, Maastricht University, Department of Physiology, and MicroVascular Health Solutions LLC; T.M. Frech, MD, University of Utah, Department of Internal Medicine; A.J. Donato, PhD, University of Utah, Department of Internal Medicine, Department of Exercise and Sport Science, Department of Biochemistry, and VA Salt Lake City, GRECC. Address correspondence to A.J. Donato, VA Medical Center, SLC, 500 Foothill Drive, GRECC, Bldg 2, Rm 2D15A, Salt Lake City, Utah 84148, USA. E-mail: tony.donato@utah.edu. Accepted for publication June 21, 2017.
Hans Vink
From the University of Utah, Department of Internal Medicine, and the Department of Exercise and Sport Science, and the Department of Biochemistry; VA Salt Lake City, Geriatric Research, Education, and Clinical Center (GRECC), Salt Lake City, Utah, USA; Maastricht University, Department of Physiology, Maastricht, the Netherlands; MicroVascular Health Solutions LLC, Alpine, Utah, USA. Supported by the US National Institutes of Health (R01 AG040297 to AJD, K23 AR067889 to TMF, and K02 AG045339 to AJD); and the US Department of Veterans Affairs (I01 CX001183 to TMF). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. HV is chief scientific officer at MicroVascular Health Solutions LLC and reports personal fees from GlycoCheck BV and MicroVascular Health Solutions LLC outside the submitted work. In addition, HV has a patent (WO2009068685): Diagnostic and Therapeutic Tools for Diseases Altering Vascular Function. D.R. Machin, PhD, University of Utah, Department of Internal Medicine, and VA Salt Lake City, GRECC; P.E. Gates, PhD, University of Utah, Department of Internal Medicine; H. Vink, PhD, Maastricht University, Department of Physiology, and MicroVascular Health Solutions LLC; T.M. Frech, MD, University of Utah, Department of Internal Medicine; A.J. Donato, PhD, University of Utah, Department of Internal Medicine, Department of Exercise and Sport Science, Department of Biochemistry, and VA Salt Lake City, GRECC. Address correspondence to A.J. Donato, VA Medical Center, SLC, 500 Foothill Drive, GRECC, Bldg 2, Rm 2D15A, Salt Lake City, Utah 84148, USA. E-mail: tony.donato@utah.edu. Accepted for publication June 21, 2017.
Tracy M. Frech
From the University of Utah, Department of Internal Medicine, and the Department of Exercise and Sport Science, and the Department of Biochemistry; VA Salt Lake City, Geriatric Research, Education, and Clinical Center (GRECC), Salt Lake City, Utah, USA; Maastricht University, Department of Physiology, Maastricht, the Netherlands; MicroVascular Health Solutions LLC, Alpine, Utah, USA. Supported by the US National Institutes of Health (R01 AG040297 to AJD, K23 AR067889 to TMF, and K02 AG045339 to AJD); and the US Department of Veterans Affairs (I01 CX001183 to TMF). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. HV is chief scientific officer at MicroVascular Health Solutions LLC and reports personal fees from GlycoCheck BV and MicroVascular Health Solutions LLC outside the submitted work. In addition, HV has a patent (WO2009068685): Diagnostic and Therapeutic Tools for Diseases Altering Vascular Function. D.R. Machin, PhD, University of Utah, Department of Internal Medicine, and VA Salt Lake City, GRECC; P.E. Gates, PhD, University of Utah, Department of Internal Medicine; H. Vink, PhD, Maastricht University, Department of Physiology, and MicroVascular Health Solutions LLC; T.M. Frech, MD, University of Utah, Department of Internal Medicine; A.J. Donato, PhD, University of Utah, Department of Internal Medicine, Department of Exercise and Sport Science, Department of Biochemistry, and VA Salt Lake City, GRECC. Address correspondence to A.J. Donato, VA Medical Center, SLC, 500 Foothill Drive, GRECC, Bldg 2, Rm 2D15A, Salt Lake City, Utah 84148, USA. E-mail: tony.donato@utah.edu. Accepted for publication June 21, 2017.
Anthony J. Donato
From the University of Utah, Department of Internal Medicine, and the Department of Exercise and Sport Science, and the Department of Biochemistry; VA Salt Lake City, Geriatric Research, Education, and Clinical Center (GRECC), Salt Lake City, Utah, USA; Maastricht University, Department of Physiology, Maastricht, the Netherlands; MicroVascular Health Solutions LLC, Alpine, Utah, USA. Supported by the US National Institutes of Health (R01 AG040297 to AJD, K23 AR067889 to TMF, and K02 AG045339 to AJD); and the US Department of Veterans Affairs (I01 CX001183 to TMF). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. HV is chief scientific officer at MicroVascular Health Solutions LLC and reports personal fees from GlycoCheck BV and MicroVascular Health Solutions LLC outside the submitted work. In addition, HV has a patent (WO2009068685): Diagnostic and Therapeutic Tools for Diseases Altering Vascular Function. D.R. Machin, PhD, University of Utah, Department of Internal Medicine, and VA Salt Lake City, GRECC; P.E. Gates, PhD, University of Utah, Department of Internal Medicine; H. Vink, PhD, Maastricht University, Department of Physiology, and MicroVascular Health Solutions LLC; T.M. Frech, MD, University of Utah, Department of Internal Medicine; A.J. Donato, PhD, University of Utah, Department of Internal Medicine, Department of Exercise and Sport Science, Department of Biochemistry, and VA Salt Lake City, GRECC. Address correspondence to A.J. Donato, VA Medical Center, SLC, 500 Foothill Drive, GRECC, Bldg 2, Rm 2D15A, Salt Lake City, Utah 84148, USA. E-mail: tony.donato@utah.edu. Accepted for publication June 21, 2017.
Published eLetters
eLetters are comments published online only and are not peer-reviewed. Publication of eLetter submissions is not guaranteed, and all submissions are reviewed and edited at the discretion of The Journal's staff.
If you wish to publish Letters to the Editor or Correspondence, please submit through our online submission system ScholarOne Manuscripts.
Jump to comment:
No eLetters have been published for this article.
In this issue
The Journal of Rheumatology
Vol. 51, Issue 4
1 Apr 2024
Automated Measurement of Microvascular Function Reveals Dysfunction in Systemic Sclerosis: A Cross-sectional Study
Daniel R. Machin, Phillip E. Gates, Hans Vink, Tracy M. Frech, Anthony J. Donato
The Journal of Rheumatology Sep 2017, jrheum.170120; DOI: 10.3899/jrheum.170120